Sponsors
Pfizer is leveraging its array of top class scientists in disciplines such as chemistry, computational biology, enzymology, and molecular modeling to impact an emerging area of scientific research called Systems Biology. The Systems Biology approach provides researchers with a more comprehensive outlook on drug safety, efficacy and selectivity with a goal of bringing quality medicines to patients more quickly. Pfizer's Research Technology Center (RTC) in Cambridge, Massachusetts is focused on building partnerships with colleagues across Pfizer and the broader scientific community to bring cutting-edge technological solutions to global drug discovery and is applying a Systems Biology approach to new drug generation targeted against kinases.
For more information please go to www.pfizerrtc.com.
SimBiologyTM extends MATLAB® with tools for modeling, simulating, and analyzing biochemical pathways. SimBiology provides industry-proven mathematics with an intuitive graphical user interface. Modelers and scientists can aggregate pathway knowledge and communicate their research within the same software platform. Using SimBiology, you can create your own block diagram model using predefined blocks. You can manually enter species, parameters, reactions, rules, kinetic laws, and units, or read in Systems Biology Mark-Up Language (SBML) models. SimBiology lets you simulate a model using stochastic or deterministic solvers and analyze your pathway with tools such as parameter estimation and sensitivity analysis.
For more information please visit www.mathworks.com/products/simbiology.
Recent advances in the "omics" technologies, scientific computing and mathematical modeling of biological processes have started to fundamentally impact the way we approach drug discovery. These include genome-scale functional screens, protein microarrays and the necessary large collections of reagents, pathway and protein interaction databases as well as algorithms for data and text mining. These developments enable, for the first time, the analysis of specific mechanisms in the context of complex biological systems. While the experimental, modeling, and simulation methods and tools are advancing, it is their iterative and combinatorial application that defines the systems biology approach.
For more information please visit www.nibr.novartis.com.
Merrimack Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery and development of novel treatments for diseases in the areas of autoimmune disease and cancer. The Company has a robust pipeline with a lead product in phase 2 and several biotherapeutics in development. The company's proprietary Network Biology discovery platform, developed with the help of leading scientists from MIT and Harvard, enables the high throughput profiling of protein networks as a basis for improved validation, lead identification and speed in the development of innovative, effective and safe therapeutics. Merrimack is privately held and based in Cambridge, Massachusetts.
For additional information, please visit www.merrimackpharma.com.
Entelos builds predictive mathematical models of human physiology and uses "virtual patients" to accelerate pharmaceutical R&D. Our teams of life scientists and engineers develop and use PhysioLab® systems to simulate and predict human response and bring a fundamentally new way of looking at biology, health, and disease. Entelos provides in silico models and therapeutic expertise in immunologic, respiratory, and metabolic disorders to global pharmaceutical and biotechnology companies.
For more information, please see www.entelos.com.
In association with
National Centers for Systems Biology
The National Centers for Systems Biology are funded by the National Institute of General Medical Sciences, a component of the National Institutes of Health. NIGMS supports basic biomedical research, the foundation for advances in disease diagnosis, treatment, and prevention. It launched the systems biology program in 2002 to promote systems level analysis of a variety of biological phenomena. The NIGMS vision for these centers includes a strong commitment to training and outreach, including the creation of educational and research resources. More information about the NIGMS program and the seven centers currently funded is available at www.nigms.nih.gov/Initiatives/SysBio. Publication of this Guide is part of the outreach and knowledge dissemination effort of the CDP Center and was made possible in part by NIGMS grant P50-GM068762.
Top of page
